CrestPoint Capital Management’s Biogen BIIB Stock Holding History

CrestPoint Capital Management’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	$1.08M	Hold	3,400	–	–	0.6%	55
2017 Q3	$1.06M	Sell	3,400 -500	-13%	-$148K	0.47%	73
2017 Q2	$1.06M	Sell	3,900 -115	-3%	-$30.4K	0.5%	69
2017 Q1	$1.1M	Buy	4,015 +415	+12%	+$117K	0.52%	60
2016 Q4	$1.02M	Hold	3,600	–	–	0.51%	61
2016 Q3	$1.13M	Buy	3,600 +200	+6%	+$59.2K	0.58%	53
2016 Q2	$822K	Sell	3,400 -400	-11%	-$105K	0.44%	87
2016 Q1	$989K	Hold	3,800	–	–	0.54%	59
2015 Q4	$1.16M	Sell	3,800 -1,200	-24%	-$345K	0.66%	46
2015 Q3	$1.46M	Sell	5,000 -1,500	-23%	-$495K	0.84%	33
2015 Q2	$2.63M	Hold	6,500	–	–	1.39%	7
2015 Q1	$2.75M	Buy	6,500 +2,655	+69%	+$1.05M	1.43%	8
2014 Q4	$1.3M	Buy	3,845 +645	+20%	+$209K	0.71%	38
2014 Q3	$1.06M	Hold	3,200	–	–	0.64%	56
2014 Q2	$1.01M	Sell	3,200 -200	-6%	-$60.2K	0.59%	65
2014 Q1	$1.04M	Hold	3,400	–	–	0.65%	51
2013 Q4	$951K	Buy	+3,400	New	+$879K	0.63%	55

Other funds holding BIIB

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

CrestPoint Capital Management's BIIB Position: Q4 2017 in Review

CrestPoint Capital Management held its Biogen (BIIB) position steady in Q4 2017 at 3,400 shares worth $1.08M. The position accounts for 0.6% of the portfolio, ranked #55.

CrestPoint Capital Management first reported a position in BIIB in Q4 2013 and has held it in 17 quarters since. The position peaked at $2.75M in Q1 2015. 1,122 funds tracked by Wall St. Rank hold BIIB as of Q4 2017.

CrestPoint Capital Management held 3,400 shares of Biogen worth $1.08M as of Q4 2017.
CrestPoint Capital Management left its Biogen share count unchanged in Q4 2017.
Biogen made up 0.6% of CrestPoint Capital Management's portfolio in Q4 2017, its #55 holding.
CrestPoint Capital Management first reported a position in Biogen in Q4 2013 and has held it in 17 quarters since.
CrestPoint Capital Management's Biogen position peaked at $2.75M in Q1 2015.
1,122 funds tracked by Wall St. Rank held Biogen as of Q4 2017.

Based on CrestPoint Capital Management's 13F filing for Q4 2017, filed 17 Jan 2018.